FDA Should Consider Accelerated Withdrawal Process, Agency Official Says

Drug Industry Daily
The FDA should consider a speedier way to withdraw indications granted under accelerated approval in light of the recent resource-intensive, time-consuming effort to revoke the metastatic breast cancer (MBC) indication for Genentech’s Avastin, CBER Director Karen Midthun says.

To View This Article:


Subscribe To Drug Industry Daily